Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Investor Presentation (May 2022)
34 slides from Eris Lifesciences's investor presentation, May 18, 2022
Slide 1: Exchange filing cover letter: Corporate Presentation
Date: 18th May, 2022 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra Kurla Complex Mumbai- 400001 Bandra (E) Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: CORPORATE PRESENTATION Dear Sir/Madam, Pursuant to the requir
Slide 2: Eris Lifesciences Corporate Presentation May 2022
Eris Lifesciences Corporate Presentation May 2022
Slide 3: Business Highlights
Business Highlights Founded in 2007; profitable from the second year of Revenue CAGR 12% in last 2 years operations 13,470 10,741 Only Indian listed pharmaco with a pure-play Domestic Branded Formulations model Rank 21 in IPM - Youngest among India’s Top-25 domestic branded formulation pharmac
Slide 4: Financial Snapshot
Financial Snapshot FY 22 Dividends as % of net profits ₹ mn ₹ mn 21% 13,470 4,850 20% 16% Op Revenue 11.2% EBITDA 12.6% yoy growth yoy growth ₹ mn 4,058 PAT’ 14.3% FY20 FY21 FY22 yoy growth EPS (INR) Highlights Net Debt free since inception 29.9 26.2 Maintained ROIC at >= 30% over last 13 years
Slide 5: Eris has Grown at 3x the Market Rate from Pre-Covid Levels
Eris has Grown at 3x the Market Rate from Pre-Covid Levels 12.6% Eris has outperformed the IPM by 620 bps since pre-Covid times 9.8% 9.2% 9.2% 8.0% 7.9% 6.8% 6.5% 6.3% 5.0% 3.0% IPM exl. Covid IPCA TORRENT ERIS LS INTAS SUN* MANKIND USV CADILA EMCURE* MACLEODS Molecules % Acute Therapy 47% 66% 26% 7
Slide 6: Sustained Outperformance in Core Therapies from Pre-Covid Levels
Sustained Outperformance in Core Therapies ` from Pre-Covid Levels ORAL ANTI-DIABETES : 32% of Eris CARDIOLOGY : 28% of Eris VMN: 19% of Eris 7.2% over IPM 3.8% over IPM 10.9% 11.8% 4.4% over IPM 9.9% 7.1% 5.5% 4.6% IPM Eris IPM Eris IPM Eris CNS: 8% of Eris WOMEN’S HEALTH: 4% of Eris Eris has gro
Slide 7: Chronic and Sub-Chronic focused therapy mix
Chronic and Sub-Chronic focused therapy ` mix Contribution of Chronic + Sub-chronic vs. Acute Therapy-wise composition of revenue Others Women’s Health 10% Anti Diabetes 5% CNS 28% 7% Chronic & 77% Sub-chronic 89% Derma 8% 17% 25% 23% Acute 11% VMN Cardiac Care MAT Apr’17 MAT Apr’22 Contribution of
Slide 8: Top-15 Power Brands Portfolio Contribute ~66% of Revenue
Top-15 Power Brands Portfolio Contribute ~ 66% of Revenue Our Top 15 Mother Brands contribute ~ 66% of our revenue Blockbuster additions to power brand portfolio in the last two years MAT Apr’22 Sales (₹ mn) Market share ` 2,762 6% 1,485 4% • Crossed INR 71+ crore of annual revenue; scaled up 8x in
Slide 9: Strong Position in the ~INR 10,100 Crore Oral Anti-Diabetes Market
Eris Enjoys a Strong Position in the ~ INR 10,100 Crore Oral Anti-Diabetes Market Eris ranks in Oral Anti-Diabetes therapy Eris has built a full-service presence in Oral Anti-Diabetes therapy with high market ranks in latest generation molecules (DPP4 and By Revenue* Total # Rx** Rx Productivity** S
Slide 10: Jan 2022 – Leveraging the Insulin/GLP1 Opportunity with MJ Biopharm
Jan 2022 – Leveraging the Insulin/ GLP1 Opportunity with MJ Biopharm • Leading position in Indian oral anti-diabetes • Proven capabilities in developing advanced biological formulations from preclinical through to • Strong credibility with Diabetologists/ Phase III and regulatory approval Endocrinol
Slide 11: May 2022 – Entered Dermatology Through Acquisition of Oaknet Healthcare
May 2022 – Entered Dermatology Through the 100% Acquisition of Oaknet Healthcare Oaknet Deal Rationale for Eris Oaknet Business Overview • With the Oaknet deal, Eris extends its presence to • Revenue base of INR 1,950 mn in FY22 (P) 87% of the Rs. 55,000 crore Chronic Market, with a • Ranked among t
Slide 12: Eris Enjoys High Prescription Ranks among Super-Specialists
Eris Enjoys High Prescription Ranks among Super-Specialists Eris Prescription Ranks* among leading Doctor Specialties 3 4 4 DIABETOLOGISTS # CARDIOLOGISTS NEUROLOGISTS 5 6 CONSULTING GASTROENTEROLOGISTS PHYSICIANS 11 Source: SMSRC MAT Feb 2022│* In the represented market│# Diabetologists include End
Slide 13: Created significant value from past acquisitions
Created significant value from past acquisitions Acquisition Rationale Value Creation • Launched several new products in Neurology and Psychiatry to build a CNS franchise growing at 33% • Entry into CNS p.a. Domestic therapy • Flagship brand Renerve has grown from Rs. 77 2017 Formulations crore p.a.
Slide 14: Three Pillars of Our Market Engagement
Three Pillars of Our Market Engagement The core focus of our market engagement is to enable clinicians to improve clinical outcomes in patients through timely and precision diagnosis and treatment 1 2 3 Dissemination of latest Generation of scientific knowledge Patient Care initiatives actionable sc
Slide 15: Leading the Digital Dissemination of Scientific Knowledge
1. Leading the Digital Dissemination of Scientific Knowledge since the Start of the Pandemic • As a prominent stakeholder in the enhancement of scientific knowledge, Eris has facilitated ~3,600+ digital (group) interactions since the start of the pandemic covering 52,000+ doctors • Discussion topics
Slide 16: The India Diabetes Study
2a. Pioneering India-Centric Studies to Generate Actionable Scientific Evidence – The India Diabetes Study First of its kind nation-wide study Cardiovascular risk in newly diagnosed type 2 diabetes patients in India 5080 Patients │ 1932 Physicians │ 928 Medical centres │ 121 Cities across 27 Indian
Slide 17: The India Heart Study
2b. Pioneering India-Centric Studies to Generate Actionable Scientific Evidence – The India Heart Study IHS Methodology IHS Revealed Expert Speak The investigators examined the blood 42% of the participants were White-coat hypertensives get pressure of 18,918 participants with misdiagnosed and were
Slide 18: Patient Care – Driving Precision Diagnosis and Better Disease Management
3. Patient Care – Driving Precision Diagnosis and Better Disease Management 6,814 1,09,049 Objective - to bring cutting-edge healthcare solutions to our patients through the involvement of Key Opinion Leaders 2,49,379 55,229 Focused on state-of-the-art diagnostic facilities and subsequent treatm
Slide 19: Our Manufacturing Infrastructure
Our Manufacturing Infrastructure
Slide 20: Pan-India Sales Presence and Distribution Network
Pan-India Sales Presence and Distribution Network Stockists Region-wise sales distribution (FY22) 11 Super Stockists 1 6 81 47 23 1 10% 56 120 200 49 56 2 4 22% 39% 89 29 133 124 1 33 97 251 70 4 29% 94 99 2 Central Warehouses 1 241 22 Sales Depots 138 South West North East 2,059 Stockists 5,00,000+
Slide 21: Board of Directors
Board of Directors • Eight-member Board of Directors, comprising of four Executive Directors and four Independent Directors, Amit Bakshi Krishnakumar V Inderjit Singh Negi Kaushal Shah including two women directors Chairman and Executive Director & Executive Director Executive Director Managing Dire
Slide 22: Lifestyle Diseases Uptrend – A Large Market Opportunity
Lifestyle Diseases Uptrend – A Large Market Opportunity Expected prevalence of CVD in India Significant increase in prevalence of non-communicable 69 diseases (NCDs) in India; share of heart disease and metabolic disorders projected to expand in the years to come 29 22 19 6 8 India is called the
Slide 23: Enduring Pillars of Our Business Strategy
Hence the Enduring Pillars of Our Business Strategy CHRONIC AND SUB-CHRONIC THERAPIES 22
Slide 24: Key Growth Drivers (1/2)
Key Growth Drivers (1/2) • Our business model of building strong and sustainable brands has enabled us to significantly Expansion of outperform the market 1 power-brands’ franchise • There has been a clear shift in prescriber preference towards established brands over the last two years; this contin
Slide 25: Key Growth Drivers (2/2)
Key Growth Drivers (2/2) Expansion of • We continue to make good progress in expanding our coverage of Specialists and 3 physician Consulting Physicians in line with our expectations coverage • We are expanding our field-force by ~170 (120 Reps and 50 Managers) Therapeutic • We continue to invest in
Slide 26: Safe Harbour Statement
Safe Harbour Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions
Slide 27: Eris Lifesciences Ltd.
Eris Lifesciences Ltd. CORPORATE OFFICE: Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, Gujarat 380054 CIN: L24232GJ2007PLC049867 Website : www.eris.co.in IR Contact Kruti Raval kruti@erislifesciences.com 26
Slide 28: Appendix
Appendix 27
Slide 29: Business Structure and Holdings
Business Structure and Holdings Eris Lifesciences Limited Aprica Healthcare Promoters 10.5% Limited Earlier known as UTH Public 13.3% Healthcare Limited Eris M. J. Biopharm Private Limited 52.7% FPI Earlier known as Kinedex Healthcare Private Limited 23.5% Eris Therapeutics DIIs Limited Oaknet Healt
Slide 30: Financial Summary (1/2)
Financial Summary (1/2) P&L Summary FY17 FY18 FY19 FY20 FY21 FY22 Revenue 7,495 8,556 9,822 10,741 12,119 13,470 Gross Profit 6,449 7,215 8,285 9,025 9,736 10,885 Gross Profit Margin (%) 86.0% 84.3% 84.4% 84.0% 80.3% 80.8% Operating EBITDA 2,691 3,220 3,449 3,684 4,306 4,850 Operating EBITDA Margin
Slide 31: Financial Summary (2/2)
Financial Summary (2/2) FY17 FY18 FY19 FY20 FY21 FY22 BS Summary Mar'17 Mar'18 Mar'19 Mar'20 Mar'21 Mar’22 Margin (%) Share Capital 138 138 138 136 136 136 Gross Margin 86.0% 84.3% 84.4% 84.0% 80.3% 80.8% Reserves 5,534 8,476 11,368 12,828 15,628 18,947 EBITDA Margin 35.9% 37.6% 35.1% 34.3% 35.5% 36
Slide 32: Key Brands in Oral Diabetes Care
Key Brands in Oral Diabetes Care Therapy wide presence in Oral Diabetes Care with power brands holding high ranks in newer generation and fast- growing molecules (DPP4 and SGLT2 inhibitors) Sulfonylurea rank 6 in the ~4,800 cr Glimepiride and combinations market Glimisave MV rank 2 in Glimeperide +
Slide 33: Key Brands in Cardiovascular and VMN Therapies
Key Brands in Cardiovascular and VMN Therapies High rank in Anti-Hypertensives: the largest segment of Cardiac Care rank 5 in the ~3,700 cr Telmisartan and combinations market Eritel CH rank 5 in Telmisartan + Chlorthalidone market Eritel LN rank 2 in Telmisartan + Cilnidipine market rank 4 in the ~
Slide 34: Thank You
Eris THANK YOU Eris Lifesciences